Drug Trial Radar · NCT05005338
A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Nov 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jul 28, 2021
Primary completion
Sep 23, 2021
Study completion Sep 23, 2021
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- Denali Therapeutics Inc.
- First posted
- Aug 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single center, non-randomized, open label Phase 1 study to determine the PK and absolute bioavailability of BIIB122 (DNL151) in 2 conditions: following a single, oral dose of BIIB122 (DNL151) and following consecutive days of oral dosing, approximating steady state.
Conditions
- Healthy Volunteers
Interventions
BIIB122 (DNL151)Drug
Oral doses
[14C] BIIB122 ([14C] DNL151)Drug
Intravenous doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK Parameter: The first time to maximum observed concentration (Tmax) of BIIB122 (DNL151) in plasma following oral administrationTime frame: 1 day
- PK Parameter: Maximum observed concentration (Cmax) of BIIB122 (DNL151) in plasma following oral administrationTime frame: 1 day
- PK Parameter: Area under the concentration-time curve (AUC) of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151 in plasma following oral and intravenous administrationTime frame: 1 day
- PK Parameter: Time from baseline at which half of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151 has been eliminated (t1/2) in plasma after oral and intravenous administrationTime frame: 1 day
- PK Parameter: Clearance (CL/F and CL) of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151) from plasma after oral and intravenous administrationTime frame: 1 day
- PK Parameter: Volume of distribution (Vd/F and Vd) of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151) from plasma after oral and intravenous administrationTime frame: 1 day
- PK Parameter: Absolute bioavailability (F) of BIIB122 (DNL151) after oral administrationTime frame: 1 day
- PK Parameter: The first time to maximum observed concentration (Tmax) of BIIB122 (DNL151) in plasma following oral administrationTime frame: 21 days
- PK Parameter: Maximum observed concentration (Cmax) of BIIB122 (DNL151) in plasma following oral administrationTime frame: 21 days
- PK Parameter: Concentration of BIIB122 (DNL151) in plasma at the end of dosing intervalTime frame: 21 days
- PK Parameter: Area under the concentration-time curve of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151) in plasma following oral and intravenous administrationTime frame: 21 days
- PK Parameter: Time from baseline at which half of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151) has been eliminated (t1/2) in plasma after oral and intravenous administrationTime frame: 21 days
- PK Parameter: Volume of distribution (Vd/F and Vd) of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151) from plasma after oral and intravenous administrationTime frame: 21 days
- PK Parameter: Clearance (CL/F and CL) of BIIB122 (DNL151) and [14C]-BIIB122 ([14C]-DNL151) from plasma after oral and intravenous administrationTime frame: 21 days
- PK Parameter: Absolute bioavailability (F) of BIIB122 (DNL151) after oral administrationTime frame: 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaron CPC
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.